TL;DR
Get smart everyday buys delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Novo Nordisk reported that it bought 1.225 million B shares for about DKK 307.4 million between September 29 and October 2. Since February 4, the company says it has repurchased 36.6 million B shares for DKK 10.25 billion under a programme of up to DKK 15 billion over 12 months.
Novo Nordisk reported on October 5 that it had repurchased 1.225 million B shares for a combined DKK 307.4 million between September 29 and October 2, as part of a wider buyback programme of up to DKK 15 billion. Since the programme began on February 4, the Danish drugmaker says it has bought back 36,604,179 B shares for DKK 10.247 billion.
The latest purchases comprised 245,000 shares on each of four trading days. Novo Nordisk reported average prices of DKK 253.30 on September 29, DKK 252.74 on September 30, DKK 250.50 on October 1 and DKK 248.77 on October 2. Their transaction values were about DKK 62.1 million, DKK 61.9 million, DKK 61.4 million and DKK 60.9 million, respectively.
Including the latest transactions, purchases under the programme announced on May 6 total 21,845,000 B shares, with a transaction value of DKK 6,447,270,879, the company said. That programme allows repurchases of up to DKK 11,200,000,010.45 between May 6, 2026, and February 1, 2027, and forms part of the broader plan covering the 12 months from February 4.
Novo Nordisk said its holdings of treasury shares rose to 50,644,876 B shares, or 1.1% of its share capital. The company reported that its total A and B share count is 4.465 billion, including treasury shares. It said detailed information on each transaction is published on its website.
Buybacks Reach DKK 10.25 Billion
The latest filing gives investors a dated account of the pace and cost of Novo Nordisk’s purchases, while the cumulative figure shows that the company has used about DKK 10.25 billion of its stated DKK 15 billion programme since February 4. The reported total is a measure of shares bought and transaction value to date; it does not establish what effect the purchases have had on the share price or on future financial performance.
Share repurchases reduce the number of shares held by outside investors when the bought shares are retained as treasury shares or later cancelled. Novo Nordisk reported that its treasury holdings represented 1.1% of share capital after the latest transactions. The announcement does not say whether the company plans to cancel these shares, use them for other purposes, or change the overall programme.
As an affiliate, we earn on qualifying purchases.
A Two-Stage Repurchase Plan
Novo Nordisk said it began an overall share repurchase programme on February 4, 2026, with purchases of up to DKK 15 billion planned during a 12-month period. On May 6, it initiated a programme within that broader plan, with a stated maximum of DKK 11.2 billion and an end date of February 1, 2027.
The company said the buyback was conducted under the EU Market Abuse Regulation and the related Safe Harbour Rules. Its October 5 release is a transaction update: it reports purchases made since the prior announcement on September 28 and gives cumulative totals through October 2. The company’s B shares trade on Nasdaq Copenhagen; its American depositary receipts trade on the New York Stock Exchange.
““Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026.””
— Novo Nordisk
The announcement does not explain how Novo Nordisk intends to use the 50.6 million treasury shares it reported holding, or whether it plans to cancel any of them. It also does not provide a forecast for future purchase volumes or prices; the stated DKK 15 billion is a programme ceiling, not a commitment that the full amount will be spent.
The transaction report covers purchases through October 2. Any purchases after that date, and the programme’s eventual total cost and share count, are not included in this update. The release does not provide an assessment of the buyback’s effect on the company’s valuation or market price.
Purchases May Continue Through February
Novo Nordisk’s May 6 programme is scheduled to run through February 1, 2027, subject to its stated maximum of about DKK 11.2 billion. The broader plan covers a 12-month period beginning February 4, 2026. The company says transaction details are published on its website, where subsequent updates can show whether it continues buying shares and how cumulative totals change.
The next material information will be further transaction disclosures or a company announcement that changes the programme’s terms. Novo Nordisk has not specified in this release when it will publish its next update.
Key Questions
The company reported repurchasing 1,225,000 B shares from September 29 through October 2, 2026.
How much has Novo Nordisk spent on buybacks since February?
Novo Nordisk reported a cumulative transaction value of DKK 10,247,270,869 for 36,604,179 B shares repurchased since February 4, 2026.
What is the maximum size of the overall programme?
The overall programme is for repurchases of up to DKK 15 billion during a 12-month period beginning February 4, 2026.
When does the programme announced on May 6 end?
The May 6 programme allows purchases through February 1, 2027, for an amount up to DKK 11,200,000,010.45.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
